There are no further questions in the queue at this time. I will turn the call back over to Hadar for any closing remarks. Hadar Levy I would like to thank all of the investors, analysts and other participants for their interest in BrainsWay. With that, please enjoy the rest of your day. Thank you. Operator Thank you, ladies and gentlemen. This concludes your teleconference. Please disconnect your lines. Okay. Got it. And then Ido on the financial side, could you just give us a sense, you talked about a red ...

BrainsWay Ltd. (NASDAQ:BWAY) Q1 2023 Earnings Call May 17, 2023 8:30 AM ET Brian Ritchie - Investor Relations, LifeSci Advisors Scott Areglado - Senior Vice President and Chief Financial Officer Jeffery Cohen - Ladenburg Thalmann Boobalan Pachaiyappan - H.C. Wainwright I would now like to turn the conference over to your host, Brian Ritchie with LifeSci Advisors. Thank you. You may begin. The format for today's call will be a discussion of recent trends and business updates from Hadar, followed by a detaile ...

Revenue and Financial Performance - Revenues are expected to increase due to the expansion of the Deep TMS system marketing for MDD, OCD, and smoking addiction, with a decrease in the gap between operating expenses and revenues compared to 2022 levels [930]. - Net cash used in operating activities was $9.8 million for the year ended December 31, 2022, a decrease of $10.7 million compared to a net cash provided of $0.9 million in 2021, primarily due to higher losses and changes in working capital [931]. - The company anticipates that the trend of increased reimbursement coverage for Deep TMS could positively impact revenues, income from continuing operations, and profitability [955]. Government Grants and Royalties - As of December 31, 2022, the company received approximately $13.4 million in government grants, with $4.4 million paid in royalties, leaving outstanding royalties of up to $11.6 million [932]. - The company has engaged in research and licensing agreements with Yeda, which include royalties ranging from 1.6% to 5% for certain products [950]. Coverage and Market Expansion - Over 90 million covered lives are eligible for reimbursement for Deep TMS treatment of OCD as of March 2023, with positive coverage decisions from several major insurers [955]. - The company is actively working to facilitate increased coverage for OCD treatment by more payors, including both commercial and governmental [955]. Leadership and Organizational Changes - A leadership transition occurred in early 2023, with Mr. Ami Boehm appointed as Chairman and Mr. Hadar Levy as the new CEO [956]. - The company has seen a trend of high workforce volatility, affecting recruitment and retention of sales professionals [954]. Intellectual Property and Technology - The company has a total of 34 issued U.S. patents and 51 issued patents in other jurisdictions related to Deep TMS technology, with various expiration dates ranging from 2021 to 2039 [937]. - The company has acquired additional patents related to multichannel stimulation, which are expected to broaden the capabilities of its developing multichannel stimulator [968]. - The core technology for Deep TMS is exclusively licensed for worldwide commercialization, with rights owned by the DHHS and licensed through the PHS [969]. - The company has achieved all milestones under the PHS license agreement, which is valid until the last licensed patent expires [972]. - The company may rely on trade secrets and know-how to protect its technology, although such protection can be challenging [975]. Supply Chain and Inventory Management - The company has seen a significant rise in the price of electronic components due to supply and demand factors, leading to increased inventory levels to meet future demand [977]. - The lead time for receiving electronic components has increased significantly amid the global supply chain crisis, impacting ongoing supply capabilities [977]. Financial Controls and Ethics - The audit committee is responsible for overseeing the quality and integrity of the company's accounting, auditing, and reporting practices [773]. - The company has adopted a code of ethics applicable to its principal executive and financial officers, which is available on its website [771]. - The company has established internal controls over financial reporting to ensure reliability and compliance with generally accepted accounting principles [769].

BrainsWay Ltd. (NASDAQ:BWAY) Q4 2022 Earnings Conference Call March 15, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer Scott Areglado - Senior Vice President and Chief Financial Officer Conference Call Participants Steve Lichtman - Oppenheimer Jeffrey Cohen - Ladenburg Thalmann Boobalan Pachaiyappan - H. C. Wainwright Operator Greetings and welcome to the BrainsWay Fourth Quarter and Full-Year 2022 Earnings Call. At this time, a ...

BrainsWay Ltd. (NASDAQ:BWAY) Q3 2022 Results Earnings Conference Call November 16, 2022 8:30 AM ET Company Participants Bob Yedid - Investor Relations, LifeSci Advisors Christopher von Jako - President and Chief Executive Officer Scott Areglado - Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer & Co. Inc. Jeffery Cohen - Ladenburg Thalmann Jayson Bedford - Raymond James & Associates, Inc. Boobalan Pachaiyappan - H.C. Wainwright & Co. Jason Wittes - Loop Capital Operator Lad ...

Financial Data and Key Metrics Changes - The company reported second quarter revenue of $8 million, a 14% increase compared to $7 million in the same period of 2021, marking the eighth consecutive quarter of year-over-year growth [6][24] - Gross profit for the second quarter was $5.8 million, resulting in a gross margin of 73%, down from 81% in the prior year due to inventory obsolescence charges and increased shipping costs [24][25] - For the first half of 2022, revenues totaled $16 million, representing a 22% increase from $13.1 million in the first half of 2021 [24] Business Line Data and Key Metrics Changes - The company shipped 39 Deep TMS systems in the second quarter, bringing the total install base to 829 systems, a 22% increase from 682 systems a year ago [24] - International sales were strong, although this sales mix slightly impacted pricing and gross margins [8][24] - The company shipped 31 add-on helmets for OCD treatments, with 45% of the total install base now including OCD treatment capability [18] Market Data and Key Metrics Changes - The Israeli Ministry of Health approved coverage for the Deep TMS system for depression, which will require health funds to provide the treatment free of charge to qualifying patients [8][9] - Recent policy updates from Medicare contractors proposed reducing the number of prior medication failures for Deep TMS eligibility from four to one, which could enhance access to treatment [9][10] Company Strategy and Development Direction - The company is focused on increasing market awareness of its technology and enhancing its online presence, with organic website traffic growing by 50% year-over-year [12] - Strategic initiatives are in place to support customers with reimbursement processes, particularly for OCD treatments [20] - The company is also pursuing commercialization for Deep TMS in smoking addiction, with ongoing data collection to support future reimbursement efforts [21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged macroeconomic challenges, including inflation and recession concerns, which have impacted customer decision-making and sales [22][32] - Despite these challenges, the company remains optimistic about long-term commercial success, supported by a strong balance sheet [22][28] - Management indicated that the current economic environment may lead to a more cautious approach in the second half of 2022 regarding investments in commercial and research activities [27][29] Other Important Information - The company participated in seven medical meetings during the second quarter and plans to continue its presence at medical conferences [14] - The company is actively working on expanding reimbursement for OCD treatments, with recent positive coverage policies from major health plans [19] Q&A Session Summary Question: Impact of macro headwinds on customers and sales - Management noted that decision-making has been delayed due to macroeconomic factors, affecting the conversion of new customers [32] Question: Shift towards leasing versus outright purchases - There has been a slight shift towards leasing, but overall decision-making has been delayed [33][34] Question: Updates on coverage policies - The proposed updates to Medicare policies apply to all TMS treatments, not just Deep TMS [35][36] Question: Gross margin guidance for the year - Management indicated that gross margin pressure is expected to continue due to increased shipping costs and inventory issues [37][38] Question: International sales performance - Approximately a quarter of the systems shipped were for international markets, indicating stronger international sales [42] Question: Update on sales force size - The company currently has 17 regional territory managers and aims to increase this number [45] Question: Commentary on international market opportunities - Israel's recent approval for reimbursement positions it as a significant opportunity, although it remains a small market [63][64]

Elevating Mental Health Treatment May 2022 Nasdaq/TASE: BWAY Disclaimer Safe Harbor and Non-GAAP Financial Measures This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to subscribe for or acquire any of the Company's securities or to participate in any investment in the Company. No representation or warranty is made to the accuracy or completeness of this presentation. You must make your own investigation and assessment of the matters contained here ...

BrainsWay Ltd. (NASDAQ:BWAY) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Bob Yedid – LifeSci Advisors Chris von Jako – President and Chief Executive Officer Scott Areglado – Chief Financial Officer Conference Call Participants Jeffery Cohen – Ladenburg Thalmann Jayson Bedford – Raymond James Steven Lichtman – Oppenheimer Jason Wittes – Loop Capital Carl Byrnes – Northland Capital Markets Operator Greetings, and welcome to BrainsWay First Quarter 2022 Earnings Conference Cal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ...

BrainsWay Ltd. (NASDAQ:BWAY) Q4 2021 Earnings Conference Call March 9, 2022 8:30 AM ET Company Participants Bob Yedid – Managing Director-LifeSci Advisors, LLC Christopher von Jako – President and Chief Executive Officer Scott Areglado – Chief Financial Officer Conference Call Participants Jeffery Cohen – Ladenburg Thalmann Jayson Bedford – Raymond James Jason Witz – Loop Capital Carl Byrnes – Northland Capital Steven Lichtman – Oppenheimer & Co. Boobalan Pachaiyappan – H.C. Wainwright Operator Greetings, a ...